MODULE 1

1.3 - Product Information

1.3.1
SPC, Labelling and Package Leaflet

1.3.1.2
SPC
Pertagen® (acellular Pertussis Vaccine)
SUMMARY OF PRODUCT CHARACTERISTICS
Pertagen®

1. NAME OF THE MEDICINAL PRODUCT
Pertagen® Recombinant acellular pertussis vaccine.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each single dose (0.5 mL) contains:
Purified *Bordetella pertussis* antigens
- Recombinant Pertussis Toxin (rPT)* 5 µg
- Filamentous Haemagglutinin (FHA) 5 µg
* rPT is a genetically-detoxified PT obtained by recombinant DNA technology.
adsorbed on aluminum hydroxide.
For the full list of excipients, see section 6.1.
Pertagen® meets the World Health Organisation requirements for the manufacture of biological substances and acellular pertussis vaccines.

3. PHARMACEUTICAL FORM
Suspension for injection.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications
Pertagen® is indicated for active booster immunization against pertussis in individuals from the age of 11 years onwards.
Pertagen® may be considered as an alternative to combined tetanus, diphtheria and acellular pertussis vaccines in persons having received multiple and frequent tetanus and diphtheria vaccine doses including persons with known hypersensitivity to tetanus (Arthus-type hypersensitivity reaction) or diphtheria vaccines.

4.2 Posology and method of administration
Posology
A single 0.5 mL dose of Pertagen® is recommended. Pertagen® should be given following the current local recommendation for booster vaccination against pertussis.
In accordance with 2019 WHO recommendations for routine immunization of pertussis-containing vaccine, the use of Pertagen® may be considered in the second or
third trimester and preferably at least 15 days before the end of pregnancy. See section 4.6.

**Method of administration**

Shake the syringe well to obtain a uniform, cloudy and white suspension. Do not use if resuspension does not occur after vigorous shaking.

**Pertagen**® should be administered by deep intramuscular injection, preferably in the deltoid region. Before injection, the skin over the site of injection should be cleaned with a suitable germicide. Open the needle cap of the pre-filled syringe, administer the total volume of 0.5 mL intramuscularly (IM).

### 4.3 Contraindications

**Hypersensitivity**

**Pertagen**® should not be administered to individuals having shown signs of hypersensitivity or life-threatening reaction following administration of pertussis vaccines or to any component of the vaccine (see section 2 “QUALITATIVE AND QUANTITATIVE COMPOSITION” and section 6.1 “List of excipients”).

Hypersensitivity to diphtheria and tetanus vaccines are not contra-indication to the use of **Pertagen**®.

**Neurological Disorders**

**Pertagen**® should not be administered to individuals having experienced any encephalopathy with unknown aetiology such as coma, prolonged seizures, or decreased level of consciousness within 7 days following previous vaccination with any whooping cough vaccine.

**Pertagen**® should not be administered to individuals with progressive or unstable neurological disorders, uncontrolled epilepsy or progressive encephalopathy.

### 4.4 Special warnings and precautions for use

**General**

It is good clinical practice that vaccination should be preceded by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events) and a clinical examination in compliance with local requirements. As with all injectable vaccines, appropriate medical care should be readily available in case of a rare anaphylactic reaction after vaccination.

- The vaccine should not be administered intravascularly.
- Fractional doses (<0.5 mL) should not be given.

**Febrile and acute reactions**

As with other vaccines, administration of **Pertagen**® to subjects suffering from acute severe febrile illness should be postponed.

**Pertagen**® should be administered with precautionary measures to subjects who had any of the following adverse events within 48 hours after a previous immunization with any whooping cough vaccines: high temperature (≥ 40°C) without any identifiable cause, convulsions and collapse or shock-like state.
Hematologic reactions

**Pertagen®** should be administered with caution to the recipient with any bleeding disorders, thrombocytopenia or anticoagulant therapy because bleeding at injection site may occur after intramuscular injection.

Immunodeficiency

In the case of immunosuppressive treatment or immunodeficiency, the immune response to the vaccine may be diminished. Vaccination should be postponed until the end of treatment or resolution of disease. Nevertheless, in the case of chronic immunodeficiency, including HIV-infected persons, vaccination is recommended even if the response may be limited.

### 4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies with other medicinal products or vaccines have not been performed. However, since **Pertagen®** is an inactivated vaccine, administration of **Pertagen®** concomitantly with other inactivated vaccine or immunoglobulin is unlikely to cause any interference with the immune response.

When considered necessary, **Pertagen®** can be administered simultaneously with other inactivated vaccines or immunoglobulins at separate site of injections.

Immunosuppressive treatment may interfere the development of expected immune response. (see section 4.4 “Special warnings and precautions for use”)

### 4.6 Pregnancy and lactation

**Pregnancy**

Maternal immunization can protect newborns and young infants who bear the brunt pertussis mortality (WHO Immunological Basis for Immunization Series, Module 4 Pertussis, 2017). In the USA, moderate to severe local reactions have been associated with high levels of tetanus and diphtheria antitoxin when tetanus toxoid was administered with a reduced amount of diphtheria toxoid. However, because of the potential benefits of maternal pertussis immunization and the lack of monovalent acellular pertussis vaccine in the USA, the Advisory Committee on Immunization Practices (ACIP) recommends that pregnant women receive Tdap boosters during each pregnancy (WHO Global Advisory Committee on Vaccine Safety, 2014).

The previous WHO consideration supports the potential use of **Pertagen®**, a monovalent acellular pertussis vaccine, for maternal pertussis immunization.

In accordance with 2019 WHO recommendations for routine immunization of pertussis-containing vaccine, the use of **Pertagen®** may be considered in the second or third trimester and preferably at least 15 days before the end of pregnancy.

Safety data from active post-marketing surveillance (including a prospective observational study) where 964 pregnant women were exposed to **Pertagen®** (monovalent aP vaccine) or to the aP vaccine of **Pertagen®** combined with tetanus toxoid and reduced diphtheria toxoid (TdaP vaccine, **Boostagen®**) in the second or third trimester of pregnancy have shown no vaccine related adverse effect on pregnancy or the health of newborns.

No adverse effects on pregnancy, parturition, lactation, or prenatal and postnatal development were observed in one animal toxicity study evaluating **Pertagen®** antigens
combined to tetanus and diphtheria toxoids. Data in humans from randomized controlled trials on the use of Boostagen® (TdaP vaccine containing Pertagen® antigens combined to tetanus and diphtheria toxoids) during the second or third trimester of pregnancy are not yet available. However, as with other inactivated vaccines, vaccination with Pertagen® is not expected to be associated with any increased risk to the foetus.

Lactation

The effect of Pertagen® during lactation has not been assessed in humans. Nevertheless, as Pertagen® contains inactivated antigens, no risk to the breastfed infant should be expected.

4.7 Effects on ability to drive and use machines

Pertagen® has no effect on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

The safety profile presented below is based on data from a clinical trial where Pertagen® was administered to 150 adolescents between 12 and 17 years of age. Within 7 days after vaccination, the most common events occurring were local injection site pain and systemic reactions (headache, fatigue, myalgia, malaise and arthralgia). Frequency, severity and duration of adverse reactions were similar in subjects vaccinated either with Pertagen® or with a licensed Tdap vaccine. These signs and symptoms were mostly mild and moderate in intensity and resolved without sequelae.

Tabulated summary of adverse reactions

Adverse reactions are listed according to the following frequency:

- Very common (≥1/10)
- Common (≥1/100 to <1/10)
- Uncommon (≥1/1,000 to <1/100)
- Rare (≥1/10,000 to <1/1,000)
**Adolescents 12 – 17 years of age, Adverse Reactions Reported**

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Adverse Reaction/Event</th>
<th>System Organ Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common: ≥1/10</td>
<td>Pain at injection site, malaise, fatigue</td>
<td>General disorders and administration site conditions</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>Nervous system disorders</td>
</tr>
<tr>
<td></td>
<td>Myalgia, arthralgia</td>
<td>Musculoskeletal and connective tissue disorders</td>
</tr>
<tr>
<td>Common: ≥1/100 to &lt;1/10</td>
<td>Redness and induration at injection site, chills, fever (≥37.5ºC)</td>
<td>General disorders and administration site conditions</td>
</tr>
<tr>
<td></td>
<td>Vomiting</td>
<td>Gastrointestinal disorders</td>
</tr>
<tr>
<td>Uncommon: ≥1/1000 to &lt;1/100</td>
<td>Injection site swelling</td>
<td>General disorders and administration site conditions</td>
</tr>
<tr>
<td></td>
<td>Lymphadenitis</td>
<td>Blood and lymphatic system disorders</td>
</tr>
<tr>
<td></td>
<td>Pain in extremity</td>
<td>Musculoskeletal and connective tissue disorders</td>
</tr>
<tr>
<td></td>
<td>Eye pain</td>
<td>Eye disorders</td>
</tr>
</tbody>
</table>

In another clinical trial, a formulation of recombinant acellular pertussis vaccine containing PRN (Pertactin antigen) in addition to the Pertagen® antigens (rPT and FHA) was tested in 20 healthy adult subjects aged 18 – 35 years. Subjects vaccinated with this vaccine had similar frequency of adverse events following 7 days after vaccination to subjects vaccinated with a licensed Tdap vaccine.

**Adults 18 – 35 years of age, Adverse Reactions Reported**

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Adverse Reaction/Event</th>
<th>System Organ Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common: ≥1/10</td>
<td>Pain at injection site, fatigue</td>
<td>General disorders and administration site conditions</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td>Nervous system disorders</td>
</tr>
<tr>
<td></td>
<td>Myalgia</td>
<td>Musculoskeletal and connective tissue disorders</td>
</tr>
<tr>
<td>Common: ≥1/100 to &lt;1/10</td>
<td>Malaise, chills,</td>
<td>General disorders and administration site conditions</td>
</tr>
<tr>
<td></td>
<td>Arthralgia</td>
<td>Musculoskeletal and connective tissue disorders</td>
</tr>
</tbody>
</table>

**Data from post-marketing experience**

The suspected adverse reactions after authorisation of the medicinal product are monitored and reported according to pharmacovigilance practice and local regulations.

**4.9 Overdose**

Pertagen® is supplied in single-dose pre-filled syringes. Overdose requires repeated administration which cannot be excluded completely but is considered highly unlikely due to the presentation of Pertagen® in monodose pre-filled syringe.
5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmaco-therapeutic group: Bacterial vaccines, ATC code: J07AJ02

Immunogenicity of Pertagen® was evaluated in 150 adolescents aged 12 – 27 years old and compared with a licensed Tdap vaccine to show non-inferiority (Committee for Medicinal Products for Human Use (CHMP) (2005) Guideline on the choice of the non-inferiority margin: EMEA/CPMP/EWP/2158/99).

At 28 days after vaccination, ELISA anti-PT and anti-FHA antibody titers and seroconversion rates were statistically significant higher in subjects vaccinated with Pertagen® than in subjects vaccinated with the licensed Tdap vaccine. Non-inferiority of Pertagen® was met. In addition, superiority of ELISA anti-PT and anti-FHA seroconversion rates and GMTs was demonstrated according to EMEA guidelines (Committee for Proprietary Medicinal Products (CPMP) (2000) Points to consider on switching between superiority and non-inferiority: CPMP/EWP/482/99).

Non-inferiority test for seroconversion rates of anti-PT and anti-FHA antibody titers as assessed by ELISA in Pertagen® vs a licensed Tdap vaccine in 12 – 17 years old adolescents

<table>
<thead>
<tr>
<th>Seroconversion rates a</th>
<th>Pertagen® (N=148)</th>
<th>Licensed Tdap (N=149)</th>
<th>Difference b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
<td>% (95% CI)</td>
</tr>
<tr>
<td>PT</td>
<td>142 (95.95)</td>
<td>82 (55.03)</td>
<td>40.91 (32.32 – 49.51)</td>
</tr>
<tr>
<td>FHA</td>
<td>138 (93.24)</td>
<td>81 (54.36)</td>
<td>38.88 (29.92 – 47.84)</td>
</tr>
</tbody>
</table>

a: Seroconversion defined as ≥ 4 fold increase at 28 days after vaccination as compared to baseline titers
b: Based on non-inferiority test with different margin of 10%

Non-inferiority test for anti-PT and anti-FHA GMTs as assessed by ELISA in Pertagen® vs a licensed Tdap vaccine in 12 – 17 years old adolescents

<table>
<thead>
<tr>
<th>Geometric Mean</th>
<th>Pertagen® GMT a (IU/mL) (95% CI)</th>
<th>Licensed Tdap GMT a (IU/mL) (95% CI)</th>
<th>GMT Ratio b (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PT</td>
<td>527.51</td>
<td>48.09</td>
<td>10.97</td>
</tr>
<tr>
<td></td>
<td>(435.57 – 638.87)</td>
<td>(36.99 – 62.50)</td>
<td>(8.39 – ∞)</td>
</tr>
<tr>
<td>FHA</td>
<td>836.13</td>
<td>178.19</td>
<td>4.69</td>
</tr>
<tr>
<td></td>
<td>(725.13 – 964.12)</td>
<td>(148.94 – 213.19)</td>
<td>(3.88 – ∞)</td>
</tr>
</tbody>
</table>

a: Geometric Mean Change from baseline at Day 28 after vaccination
b: Based on non-inferiority test with GMT Ratio > 0.67

Protective efficacy of pertussis

No established correlates of protection to pertussis antigens are currently available. Although efficacy or effectiveness data of Pertagen® are not available for adolescents and adults including pregnant women, non-inferiority of the immune response of Pertagen® was demonstrated as per WHO recommendations (TRS 979, 2013) in adolescents in a comparative randomized controlled trial with a licensed Tdap vaccine
evaluated in effectiveness study. The antibody titers to pertussis antigens, PT and FHA, after vaccination with Pertagen® were statistically higher than those observed after immunization with the Tdap comparator vaccine. In addition, 1 month after booster vaccination, the neutralizing antibodies against PT antigen were also significantly higher with Pertagen® than with the Tdap comparator vaccine.

5.2 Pharmacokinetic properties
Evaluation of pharmacokinetic properties is not required for vaccines.

5.3 Preclinical safety data
Preclinical data reveal no special hazard for humans based on conventional studies of safety and toxicity.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Sodium chloride, water for injection. Formaldehyde may be present in trace amounts as a manufacturing process residual.

6.2 Incompatibilities
Pertagen® should not be mixed with other vaccines in the same syringe.

6.3 Shelf life
Three years. The expiry date of Pertagen® is indicated on the label and packaging.

6.4 Special precautions for storage
Pertagen® should be stored at 2°C to 8°C. Do not freeze. Discard if vaccine has been frozen. Store in the original package in order to protect from light. Keep out of the sight and reach of children.

6.5 Nature and contents of container
Single-dose (0.5 mL) pre-filled syringe which is made of a type I borosilicate glass, conforming to European Pharmacopoeia requirements. The container closure system of Pertagen® is free of latex (natural rubber).

6.6 Special precautions for use, handling and disposal
The vaccine should be well shaken to obtain a uniform, cloudy and white suspension. Do not use if you notice presence of foreign particles or discoloration. Do not inject intravascularly. Do not use after expiration date. See expiration on carton and inner label. Any unused product or waste material should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
BioNet-Asia Co., Ltd., Thailand

8. MARKETING AUTHORISATION NUMBER(S)
2A 2/59 (NBC)

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORIZATION
30 September 2016

10. DATE OF REVISION OF THE TEXT
18 December 2019

Pertagen® is BioNet-Asia’s trademark.